🔎 Trials Near Me

Utama › Kanser Metastatik › Georgia › Atlanta

Kajian klinikal Kanser Metastatik di Atlanta, GA

28 kajian untuk Kanser Metastatik sedang mencari peserta di lokasi dalam dan sekitar Atlanta (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Mengambil pesertaFasa 3
  • Piedmont Cancer Institute, Atlanta
  • Piedmont Healthcare, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT07562152

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1
  • Winship Cancer Institute of Emory University, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06270706

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Mengambil pesertaFasa 1
  • Emory University, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06465069

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Mengambil pesertaFasa 1
  • Emory Winship Cancer Institute, Atlanta
Umur 19 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06586957

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Mengambil pesertaFasa 1/2
  • Children's Healthcare of Atlanta - Egleston Hospital, Atlanta
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04094610

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

Mengambil pesertaFasa 1
  • Emory Winship Cancer Institute, Atlanta
Umur 18 ke atas · Lelaki · Dikemas kini 24 Sep 2026 · NCT07543055

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Mengambil pesertaFasa 1
  • Emory University School of Medicine - Winship Cancer Institute, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07114601

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Mengambil pesertaFasa 3
  • Winship Cancer Institute, Emory University, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07213804

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Mengambil pesertaFasa 3
  • Emory University School of Medicine- Grady Campus, Atlanta
  • Winship Cancer Institute, Emory University, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06119581

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Mengambil pesertaFasa 1
  • Emory University Hospital Midtown, Atlanta
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT04585958

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Mengambil pesertaFasa 1/2
  • Avenzo Therapeutics Recruiting Site, Atlanta
Umur 18 hingga 75 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07038343

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Mengambil pesertaFasa 3
  • Winship Cancer Institute of Emory University, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06072612

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Mengambil pesertaFasa 2
  • Emory University School of Medicine, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Ogo 2026 · NCT06769698

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

Mengambil pesertaFasa 1
  • Emory University Hospital, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT05614739

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Mengambil pesertaFasa 1/2
  • Crinetics Study Site, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT07129252

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Mengambil pesertaFasa 1
  • Winship Cancer Center - Emory University, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT06657144

A Study of PYX-201 in Advanced Solid Tumors

Mengambil pesertaFasa 1
  • Winship Cancer Institute, Emory University, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jun 2026 · NCT05720117

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Mengambil pesertaFasa 1/2
  • Winship Cancer Institute, Emory University, Atlanta
Umur 12 ke atas · Semua jantina · Dikemas kini 27 Mei 2026 · NCT05384626

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Mengambil pesertaFasa 1
  • Winship Cancer Institute at Emory University, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mei 2026 · NCT07094204

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Mengambil pesertaFasa 1/2
  • Piedmont Healthcare, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Mei 2026 · NCT05379985

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Mengambil pesertaFasa 3
  • Emory University, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Apr 2026 · NCT06064877

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Mengambil pesertaFasa 2/3
  • Emory Winship Cancer Institute, Atlanta
Semua umur · Semua jantina · Dikemas kini 2 Apr 2026 · NCT06581406

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Mengambil pesertaFasa 1/2
  • Emory Winship Cancer Institute, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Apr 2026 · NCT05735080

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Mengambil pesertaFasa 1
  • Children's Healthcare of Atlanta at Arthur M. Blank Hospital, Atlanta
Umur 1 hingga 40 · Semua jantina · Dikemas kini 12 Mac 2026 · NCT05292664

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Mengambil pesertaFasa 3
  • Emory Winship Cancer Institute, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Feb 2026 · NCT06127407

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Mengambil pesertaKajian pemerhatian
  • Massive Bio SYNERGY-AI site, Atlanta
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases

Mengambil pesertaFasa awal 1
  • Emory University Hospital/Winship Cancer Institute, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2025 · NCT06328686

A Beta-only IL-2 ImmunoTherapY Study

Mengambil pesertaFasa 1/2
  • Emory - Winship Cancer Institute, Atlanta
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Jul 2025 · NCT05086692

Kajian Kanser Metastatik di bandar lain

Kajian lain di Atlanta

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.